 | Related Articles |
Management of Patients with renal mass lesions based on renal biopsy cytology results.
Hum Pathol. 2018 Nov 27;:
Authors: Huang X, Griffin B, Lin X
Abstract
The benefit of renal biopsy, especially in patients with a history of malignancy (HOM), has not been well-studied. We studied the clinical management of 339 renal masses following fine needle aspirate (FNA) and/or core needle biopsy (CNB) with touch preparation. 41% of patients had HOM, which did not increase the incidence of renal malignancy. The main reasons for renal biopsy were HOM and small renal masses (≤ 3cm). The most common renal masses were clear cell renal cell carcinoma (CCRCC) (32%). 30% of renal masses metastasized. The overall accuracy of renal biopsy for subclassification was 76%. Nephrectomy was selected to manage 41% of renal masses, most for primary renal carcinoma (PRCa). Chemo-radiation was selected to treat 15% of patients, especially those with lymphoma (93%), metastatic malignancy (93%) and urothelial carcinoma (69%). Ablation was used to treat 6% of patients. Active surveillance was selected for 34% of patients, predominantly those with benign condition. Our results showed that renal biopsy was an easy and less aggressive tool for obtaining adequate diagnostic materials to render reliable and accurate diagnoses. Initial renal biopsy prevented unnecessary nephrectomy in patients with diagnoses of metastatic malignancy, lymphoma and majority of benign tumors/lesions (for the majority of, but not all cases). Renal biopsy avoided chemo-radiation against prior HOM in patients with diagnosis of benign tumors/lesions (22% of all patients) and PRCa (38%). Therefore, renal biopsy significantly impacts the management of patients with renal mass, and any questionable renal mass should be biopsied before further management.
PMID: 30500417 [PubMed - as supplied by publisher]
from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2RsO4X4
No comments:
Post a Comment